The potential therapeutic effect of metformin in type 2 diabetic patients with severe COVID-19

Bibliographic Information
Authors: Al-Kuraishy H.M.; Al-Gareeb A.I.; El Kholy A.A.; El-Khateeb E.; Alexiou A.; Papadakis M.; Elekhnawy E.; Alsubaie N.; Hamad R.S.; Batiha G.E.
Journal: European Review for Medical and Pharmacological Sciences
Publisher: Verduci Editore s.r.l
Publication Date: 2023
Volume / Issue: Volume 27 / Issue 23
Pages: 11445–11456
ISSN: 11283602
DOI: 10.26355/eurrev_202312_34583
Scopus: View on Scopus
PubMed: 38095392
Document Type: Article
Authors and Affiliations
Al-Kuraishy H.M., Department of Clinical Pharmacology and Medicine, College of Medicine, Al-Mustansiriyia University, Baghdad, Iraq; Al-Gareeb A.I., Department of Clinical Pharmacology and Medicine, College of Medicine, Al-Mustansiriyia University, Baghdad, Iraq; El Kholy A.A., Department of Clinical Pharmacy, Faculty of Pharmacy, Ain-Shams University, Cairo, Egypt; El-Khateeb E., Department of Clinical Pharmacy, Faculty of Pharmacy, Tanta University, Al Gharbia, Tanta, Egypt, Certara UK Limited (Simcyp Division), Sheffield, United Kingdom; Alexiou A., Department of Science and Engineering, Novel Global Community Educational Foundation, Hebersham, Australia, AFNP Med, Wien, Austria; Papadakis M., Department of Surgery II, University Hospital Witten-Herdecke, University of Witten-Herdecke, Wuppertal, Germany; Elekhnawy E., Pharmaceutical Microbiology Department, Faculty of Pharmacy, Tanta University, Tanta, Egypt; Alsubaie N., Department of Pharmacy Practice, College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia; Hamad R.S., Biological Sciences Department, College of Science, King Faisal University, Al Ahsa, Saudi Arabia, Central Laboratory, Theodor Bilharz Research Institute, Giza, Egypt; Batiha G.E., Department of Pharmacology and Therapeutics, Faculty of Veterinary Medicine, Damanhour University, AlBeheira, Damanhour, Egypt
Abstract
OBJECTIVE: Type 2 diabetes mellitus (T2DM) is regarded as a chief risk factor for(coronavirus disease 2019 (COVID-19) owing to dysregulation of the expression of angiotensin-converting enzyme 2 (ACE2) and chronic low-grade inflammatory disorders. Metformin, an insulin-sensitizing agent for managing T2DM, has pleiotropic anti-inflammatory and oxidant potentials, which may lessen the risk of diabetic complications. So, we aimed to reveal the potential role of metformin monotherapy in treating T2DM patients with COVID-19. PATIENTS AND METHODS: In this prospective cohort study, 60 hospitalized T2DM patients with COVID-19 on metformin plus standard anti-COVID-19 treatments compared to 40 hospitalized T2DM patients with COVID-19 on other diabetic pharmacotherapy like insulin and sulfonylurea, were recruited. Inflammatory and oxidative stress biomarkers and radiological and clinical outcomes were assessed at admission time and at the time of discharge. RESULTS: The results of this study illustrated that metformin treatment in T2DM patients with COVID-19 was more effective in reducing inflammatory and oxidative stress biomarkers with significant amelioration of radiological scores and clinical outcomes compared to T2DM patients with COVID-19 on another diabetic pharmacotherapy. CONCLUSIONS: Our findings highlighted that metformin efficiently managed T2DM patients with COVID-19 by reducing inflammatory and oxidative stress with mitigating effects on the radiological scores and clinical outcomes. © 2023 Verduci Editore s.r.l. All rights reserved.
Keywords
Metformin; SARS-CoV-2; T2DM; Biomarkers; COVID-19; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Prospective Studies; sulfonylurea; antidiabetic agent; biological marker; adult; anthropometric parameters; Article; cardiometabolic risk; clinical feature; clinical outcome; cohort analysis; controlled study; coronavirus disease 2019; demographics; drug efficacy; female; human; insulin treatment; major clinical study; male; non insulin dependent diabetes mellitus; outcome assessment; oxidative stress; prospective study; radiodiagnosis; complication
Citation Information
Scopus Citations: 18
For comprehensive information about the Theodor Bilharz Research Institute (TBRI), its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments, as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.
The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.
English Website: https://www.tbri.sci.eg/en/
Arabic Website: https://www.tbri.sci.eg/ar/
Prepared and Uploaded by:
Abdalla F. Abdalla
Electronic Portal Unit
